Transcranial Photobiomodulation for Reducing Autism Symptoms in Children

Exclusion Criteria

• •1. Participant child is experiencing severe self-injurious behavior or severe aggressive behavior to self or others (within past 7 days).
• •2. Participant has been diagnosed with another psychiatric or neurological disorder (e.g. epilepsy) or have exhibited symptoms of major psychiatric disorders within the last 30 days.
• •3. Participant has an unstable medical condition (that requires clinical attention).
• •4. Participant has a significant skin condition at the procedure sites (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo).
• •5. Participant has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolised AVM, implantable shunt - Hakim valve).
• •6. Participant has receiving medication on a regular basis for Autism or any other medical condition.
• •7. Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (in US: Visudine (verteporfin) - for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer).
• •8. Current treatment with a psychotropic medication.
• •9. Investigator and his/her immediate family, defined as the investigator's child or grandchild.